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Genome wide association studies (GWAS) provide an agnostic approach to identifying potential genetic variants associated with
disease susceptibility, prognosis of survival and/or predictive of drug response. Although these techniques are costly and interpretation
of study results is challenging, they do allow for a more unbiased interrogation of the entire genome, resulting in the discovery of novel
genes and understanding of novel biological associations. This review will focus on the implications of GWAS in cancer therapy, in
particular germ-line mutations, including findings from major GWAS which have identified predictive genetic loci for clinical outcome
and/or toxicity. Lessons and challenges in cancer GWAS are also discussed, including the need for functional analysis and replication, as
well as future perspectives for biological and clinical utility. Given the large heterogeneity in response to cancer therapeutics, novel
methods of identifying mechanisms and biology of variable drug response and ultimately treatment individualization will be
indispensable.
Introduction
Since its completion in 2003, an important feature of the
Human Genome Project was the dedication and commit-
ment to expanding technology across private sectors,
catalyzing technological advancements and promoting
the utility and feasibility of innovative research [1].
Methods for sequencing and scanning the genome have
become less costly, resulting in greater discoveries of novel
genetic loci that associate with the risk of disease, clinical
outcome and/or risk of toxicity [2]. The advent of genome
wide association (GWA) technology has enabled research-
ers to move beyond the limitations of small scale candi-
date gene studies to the identification of hundreds of loci
influencing a wide range of phenotypes [3].
Genome wide association studies (GWAS) provide an
agnostic approach to identifying genetic variants or single
nucleotide polymorphisms (SNPs), associated with disease
susceptibility, prognosis of survival and/or predictive of
drug response. Large sample sizes are generally required
for a GWAS to have sufficient statistical power to detect
associations while using array platforms that can interro-
gate >500 000 SNPs. The design of common GWAS plat-
forms is based on linkage disequilibrium (LD). Genotypes
can be imputed for markers not directly genotyped using
reference panels such as 1000 Genomes or HapMap [4]. It
is important to consider what proportion of SNPs not
directly genotyped are captured, or ‘tagged,’ by the chip
via LD. As a result, genotyping chips have traditionally
covered common variants, but more recently coverage has
expanded to cover more rare variants [5]. Although these
techniques are costly, they do allow for a more unbiased
interrogation of the entire genome, resulting in the discov-
ery of novel genes and biological associations [6]. A
common disadvantage to GWAS includes high rates of
false positives and low statistical power, while interpreta-
tion of study results can be extremely challenging, requir-
ing fine mapping and mechanistic studies to understand
the biological plausibility of certain findings [6].
This review will focus on the implications of GWAS in
cancer therapy, in particular germ-line mutations, includ-
ing findings from major GWAS which have identified pre-
dictive genetic loci for clinical outcome and/or toxicity, as
well as challenges and future perspectives for biological
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and clinical utility. Table 1 summarizes these GWAS find-
ings and elucidates the biological plausibility of top hits.
GWAS in cancer therapeutics
To date, the majority of cancer GWAS have characterized
mutated cancer predisposition genes accounting for
disease susceptibility [2]. Although inherited syndromes
account for only a small fraction of the familial risk of
cancer, greater than 50 genetic mutations have been asso-
ciated with high-penetrance cancer susceptibility syn-
dromes [2]. Additionally, debilitating toxicities such as
neutropenia and neurotoxicity often necessitate dose
reductions, delays or cessation of therapy, resulting in inef-
fective therapy. SNPs identified through GWAS that are
found to be predictive of toxicity or response may be asso-
ciated with increased effect sizes, ultimately allowing pro-
spective identification of toxicity risk and clinical response.
Pancreatic cancer
Cancer and Leukemia Group B (CALGB) 80303 was a
double-blind, placebo-controlled randomized phase III
study of gemcitabine with or without bevacizumab, in
which 365 patients with advanced pancreatic cancer were
genotyped [7]. Results demonstrated a significant associa-
tion (defined as P value <1 × 10−7 after adjusting for multi-
ple comparisons) between rs763780 in IL17F (P = 2.61 ×
10−8) and median overall survival (OS) [3.1 (heterozygotes)
vs. 6.8 months (wild type), respectively]. This SNP was
also in strong LD (r2 = 0.955) with another IL17F SNP
(rs7771466), having the second lowest P value (P = 1.66 ×
10−7) and a similar effect on OS.However, after adjusting for
the stratification factors, such as treatment arm, the SNPs
did not meet the criterion for genome-wide statistical sig-
nificance. A similar trend was observed in a small replica-
tion cohort of 26 patients of African ancestry [7].This study
demonstrates the feasibility in conducting a GWAS using
prospectively collected specimens from a randomized
phase III clinical trial, in which phenotypes are often more
accurately recorded. Although predictors of clinical
response in pancreatic cancer are direly needed and the
IL17F locus may be a promising genetic determinant of
response, replication in larger cohorts is necessary. Unfor-
tunately, the chances of obtaining adequate sample sizes
for replication in patients treated in the identical manner is
minimal and poses a large barrier to further validation.
Kiyotani et al. identified four genetic markers for
haematological toxicities in a GWAS of 79 Japanese
patients with cancer (the majority of which were pancre-
atic cancer cases) receiving gemcitabine, consisting of
21 patients experiencing grade 3 or 4 leukopenia/
neutropenia and 58 controls (not experiencing grade 3 or
4 leukopenia) [8]. In a replication phase, 33 patients expe-
riencing grade 3 or 4 leukopenia/neutropenia and 62 con-
trols were genotyped. Of the top 100 SNPs (P values 2.12 ×
10–4 to 6.69 × 10−6), 70 were genotyped in the replication
study, four of which were identified with associations of P <
0.05 before multiple testing (one SNP, rs11141915, was
found in the gene DAPK1 and another SNP, rs12046844,
was found in the gene PDE4B). The proportion of patients
with gemcitabine-induced leukopenia/neutropenia was
significantly increased in groups with higher prediction
scores (calculated from the combined effect of the four
loci) (trend test P = 1.31 × 10−14). The prevalence of grade
3/4 leukopenia/neutropenia was 11.5% (13/113) in the
combined group of scores 0 and 1, 60.9% (28/46) in the
score 2 group and 86.7% (13/15) in the score 3 group.
Correspondingly, the odds ratio (OR) in the score 3 group
was as high as 50.00 (P = 4.13 × 10–9) and that of the score
2 group was 11.97 (P = 6.25 × 10–10), compared with that in
the group of scores 0 and 1 [8]. Investigators took the
approach of utilizing a large biobank as opposed to a clini-
cal trial to select and enrich patients experiencing a phe-
notype of interest. The small sample size is ultimately
insufficient to determine a true causal relationship and a
variety of tumour types were included, thus allowing het-
erogeneity in dosing and treatment regimens. Prediction
scores of 0, 1, 2 and 3 (frequency, 29.0, 45.3, 20.8 and 4.9%,
respectively) demonstrated a possible cumulative effect
on the risk of gemcitabine-induced severe haematologic
toxicity, which remains to be validated in a larger and more
homogeneous cohort [9].
Breast cancer
CALGB 40101, a phase III randomized study comparing
cyclophosphamide and doxorubicin vs. single agent
paclitaxel in breast cancer patients, was the basis of
another GWAS in which 855 genetically-defined European
patients treated on the paclitaxel arm were genotyped for
>500 000 SNPs. An additional 154 self-declared European
patients and 117 African American patients from the same
study were genotyped for internal replication [9]. No SNPs
analyzed for association with initial onset of sensory
peripheral neuropathy reached genome-wide significance
(defined as P value <1 × 10−7 after adjusting for multiple
comparisons). Of these top SNPs, biologic relevance was
apparent for polymorphisms in EPHA5 (rs7349683, P = 9.6
× 10−7) and FGD4 (rs10771973, P = 2.6 × 10−6). Ordinal logis-
tic regression identified a SNP within FZD3 demonstrating
a significant association with grade of sensory peripheral
neuropathy (rs7001034, P = 3.1 × 10−9, OR, 0.57).Association
for FGD4 was confirmed in both the European and African
American samples in the internal replication set (HR 1.72, P
= 0.013 and HR 1.93, P = 6.7 × 10−3, respectively). To assess
the potential translational implications of this finding to
clinical practice, investigators estimated the cumulative
dose level triggering an event for each FGD4 genotype.
The tolerated cumulative paclitaxel dose level for patients
with zero, one and two copies of the risk allele was
1047 mg m−2, 877 mg m−2 and 710 mg m−2, respectively [9].
Similar to CALGB 80303 [7], the GWAS for 40101 collected
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samples from a prospective phase III randomized clinical
trial. Although evidence suggests a dose to event associa-
tion with variations in FGD4, which was also replicated in
two additional cohorts of patients from the same study,the
trend towards genome-wide significance in the discovery
population requires that further validation in independent
cohorts is required.
Another study by Kiyotani et al. enrolled a total of 462
Japanese patients with primary breast cancer treated with
adjuvant tamoxifen monotherapy [10]. Two hundred and
forty patients were genotyped for the discovery phase and
105 and 117 cases were used as two replication sets. Sig-
nificant associations were found between recurrence-free
survival (RFS) and 15 SNPs in nine genetic regions that
satisfied a genome-wide significant threshold of P value <5
× 10−7 (after adjusting for multiple testing of 470 796 SNPs).
Results demonstrated that rs10509373 in the C10orf11
gene on 10q22 was the only SNP significantly associated
with RFS in the replication stage (log-rank P = 4.18 × 10−4).
Investigators genotyped 130 tag SNPs for fine mapping on
chromosome 10.q22, which identified a 172-kb LD block
associated with RFS in patients receiving tamoxifen
therapy. Combined analysis of C10orf11, CYP2D6 and
ABCC2 (the latter two being previously identified to impact
RFS) revealed that variants of the three genes have cumu-
lative effects on RFS (P = 2.28 × 10−12) [risk of recurrence
increased from 6.51-fold (three risk alleles) to 119.51-fold
(five risk alleles) compared with those carrying one risk
allele] [10]. The large LD block associated with RFS, along
with the evidence of a cumulative effect with previously
known genetic variations, may provide a novel locus to
identify patients most likely to respond to tamoxifen
therapy. However, further replication and validation in
larger cohorts is necessary.
Srinivasan et al. examined epirubicin-induced leukope-
nia in 270 Japanese patients comprising 67 severe leuko-
penia cases (the majority of which were breast cancer
cases) and 203 controls (non-leukopenia) (the majority of
which were breast or liver cancer cases) [11]. Samples were
taken from the same Japanese biobank used in the study
by Kiyotani et al. [8]. The top finding identified a locus
having three SNPs (rs2916733, rs2440399, and rs2920656)
associated with leukopenia, in the MCPH1 gene on chro-
mosome 8 (P = 1.59 × 10–7, OR = 2.92; P = 4.51 × 10–7, OR =
2.81 and P = 6.59 × 10–7, OR = 4.86, respectively). No SNPs
remained significant after Bonferroni correction in a repli-
cation phase of 48 ADR patients. A haplotype constructed
from the landmark SNP (rs2916733) and rs1031309, which
was in LD with rs2916733 (r2 = 0.64), showed a stronger
association (P = 2.20 × 10−10, OR = 2.88) than the single
landmark SNP [11]. These results may provide insight into
genetic determinants of epirubicin-induced leukopenia.
However, the suggested haplotype should be validated
in a larger controlled, homogenous cohort, as the dosing
and treatment regimens may vary with a heterogenous
biobank of samples.
Ingle et al. [12] utilized a nested case-control design to
select breast cancer patients enrolled onto the MA.27
phase III trial comparing anastrozole with exemestane [13].
Cases (n = 293) were matched to controls (n = 585) in a 1:2
design and were defined as patients with grade 3 or 4
musculoskeletal adverse events (MS-AEs). Although non-
significant after testing for multiple comparison, the top
three SNPs (P values <1 × 10−6) were found on chromosome
14, and were found to be in high LD (r2 > 0.8), while an
additional imputed SNP (rs11849538) also showed an
association with MS-AEs (OR 2.21, P = 6.67 × 10−7).The three
genotyped SNPs (rs7158782, rs7159713, and rs2369049)
and the imputed SNP were all in high LD in the T-cell
leukemia 1A (TCL1A) gene (r2 = 0.85). Functional studies
demonstrated an eight-fold induction of TCL1A expression
in ER-transfected cells and significantly higher expression
after exposure to varying concentrations of o–estrogen in
lymphoblastoid cell lines (LCLs) containing the variant
SNPs when compared with cells having the wild type
sequence [12]. Although a functional analysis was com-
pleted providing insight into novel molecular mechanisms
of MS-AEs, no replication studies were completed thus
necessitating validation in a larger independent cohort.
Non-small cell lung cancer (NSCLC)
Han et al. conducted a GWAS for irinotecan-related severe
toxicities in patients with stage III/IV NSCLC [13]. Cases
(grade 3 diarrhoea or grade 4 neutropenia) and controls
were obtained from two phase II studies for the discovery
phase (n = 101). Results demonstrated 137 SNPs for diar-
rhoea and 42 SNPs for neutropenia with P < 1.0 × 10−4 [only
one reaching the established genome-wide significance
level at 10−7, after adjusting for multiple testing of 440 094
SNPs (best P = 6.9 × 10−8)]. In a replication cohort of
146 irinotecan-treated patients, rs1517114 in C8orf34,
rs1661167 in FLJ41856, and rs2745761 in PLCB1 showed
strong associations with diarrhoea. Rs11128347 in PDZRN3
and two SNPs (rs11979430 and rs7779029) located
on chromosome 7 showed strong associations with
neutropenia. High LD was observed between rs11979430
and rs7779029 (r2 = 0.911). Although UGT1A1*6 failed to
reach genome-wide significance, the combined analysis
showed that homozygous UGT1A1*6 was significantly
associated with neutropenia. Additionally, the ABCC2
3972C>T and SLCO1B1 521T>C variants were significantly
associated with diarrhoea and neutropenia, respectively, in
the replication stage [13]. As 24% and 14% of patients from
the discovery set and replication set experienced grade 4
neutropenia, respectively, and only 11% and 9% experi-
enced grade 3 diarrhoea, the sample sizes are likely insuf-
ficient to identify true causal variants and validation in
larger independent cohorts is necessary [14].
Wu et al. completed a GWAS of survival in 327 stage
III/IV NSCLC patients receiving platinum-based chemo-
therapy [14], selected from a previous GWAS [15] of lung
cancer risk. To determine which associations identified in
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the discovery phase were robust, investigators identified
60 SNPs to perform a validation study using an independ-
ent NSCLC patient cohort following the same eligibility
criteria as the discovery population (n = 315). Results dem-
onstrated that rs1878022, found in CMKLR1, was statisti-
cally significantly associated with poorer OS in the
discovery population (HR = 1.59, P = 1.42 × 10−6 after
adjusting for multiple testing of 31 751 SNPs), and the dif-
ference in median survival time (MST) was dependent on
the number of variant alleles. However, this association did
not reach significance in the validation population.
Another SNP, rs10937823, was associated with statistically
significantly poorer OS in the discovery dataset (HR = 2.40,
P = 1.80 × 10−6), the validation dataset (HR = 1.45, P = 0.04)
and the combined dataset (1.82, P = 1.73 × 10−6). In the
combined analysis, the MST for wild type patients (16.05
months) was statistically significantly longer than the MST
for those carrying the variant genotypes (10.72 months,
P = 6.76 × 10−5). To validate these findings further, both
rs1878022 and rs10937823 were analyzed in similar
patients enrolled in the PLATAX clinical trial (single arm
study of 420 advanced NSCLC patients receiving platinum
therapy). Only rs1878022 was validated in the PLATAX
population (HR = 1.23, P = 0.05) [14]. The three stage study
design in multiple independent populations allows for
validation across cohorts. However, further studies to rep-
licate these data in other patient populations with similar
treatments regimens are necessary to confirm the conclu-
sions of this study.
Similar to Wu et al. [14], Hu et al. conducted a GWAS in a
total of 535 stage III/IV NSCLC patients, taken from two
independent cohorts from a previous GWAS study on lung
cancer susceptibility [16], treated with first-line platinum-
based chemotherapy without surgery [17]. Investigators
selected 33 top SNPs that had P < 1 × 10−4 and a consistent
association with survival at P < 0.05 in both cohorts, when
tested individually. Twelve SNPs were selected for valida-
tion using an independent NSCLC cohort from Southeast-
ern China with baseline characteristics similar to the
discovery population (n = 340), five of which were found to
be associated with OS in all cohorts. These five SNPs were
then validated in a separate Caucasian cohort from Massa-
chusetts General Hospital with similar baseline character-
istics (n = 409). Four SNPs (rs7629386, rs969088,
rs12000445 and rs3850370) had the same direction of
association, but only rs762938 and rs3850370, found in
CTNNB1 and SNW1-ALKBH1-NRXN3, respectively, had sig-
nificant association with NSCLC survival (HR 1.50, P = 0.04
and HR 1.22, P = 0.03). Investigators attempted to replicate
the two SNPs from the previous NSCLC GWAS [14],
rs1878022 and rs10937823. However both were non-
significantly associated with NSCLC death risk [17]. In
another three stage GWAS, investigators were able to rep-
licate findings across patient cohorts including Han
Chinese and Caucasian samples, although the heterogene-
ity in genetic background and treatment to NSCLC
between Han Chinese and Caucasian populations may be
confounding. Additionally the effect of rs7629386 may be
unstable secondary to low frequency of homozygous Cau-
casian patients resulting in increased effect sizes in Han
Chinese vs. Caucasians.
Sato et al. [18] completed a GWAS in 105 stage III/IV
NSCLC patients treated on a clinical trial of single arm
carboplatin and paclitaxel [19]. The following three SNPs
were significantly associated with lower OS after multiple
comparison adjustment (109 365 SNPs tested): rs1656402
in the EIF4E2 gene [MST for AG (n = 50) + AA (n = 40) and
GG (n = 15) were 18.0 and 7.7 months, respectively, P = 8.4
× 10−8, HR = 4.22], rs1209950 in the ETS2 gene [MST for CC
(n = 94) and CT (n = 11) + TT (n = 0) were 17.7 and
7.4 months, respectively, P = 2.8 × 10−7, HR = 4.96] and
rs9981861 in the DSCAM gene [MST for GG (n = 75) + AG (n
= 26) and AA (n = 4) were 17.1 and 3.8 months, respectively,
P = 3.5 × 10−6,HR = 16.1].Although major differences in MST
were noted, initial sample sizes were insufficient and no
replication studies were completed post-discovery; there-
fore, further validation in larger, controlled cohorts is nec-
essary [18].
Colorectal cancer
Fernandez-Rozadilla et al. completed a GWAS to predict
toxicity after treatment with 5-fluorouracil (5-FU) or
FOLFOX (5-FU, oxaliplatin, leucovorin) in stage III/IV
colorectal cancer patients [19] collected through the
EPICOLON II project (a multicentre study of the prevalence
and clinical pathological features of colorectal cancer) [20].
The discovery and replication phase consisted of 221 and
791 patients from the same cohort, respectively (all Cauca-
sian Europeans, 58% treated with FOLFOX and 42% treated
with 5-FU). Results demonstrated that association P values
were very modest (best P = 1.076 × 10−5), with none reach-
ing the established genome-wide significance level at 10−7
after adjusting for multiple comparisons. Investigators
then genotyped the top five association hits in the replica-
tion phase. Copy number variation (CNV) regions showed
similar P values but were not well tagged by SNP markers,
and thus could not be replicated. Only one of these asso-
ciation signals was consistent in both phases: rs10876844
at 12q13.2 with 5-FU-induced diarrhoea (pooled P = 0.010,
OR 6.5, 95%CI 1.5, 27.2). Investigators also evaluated the
association signals for seven SNP variants on four genes
(DPYD, MTHFR, TYMS and GSTP1) that had been linked to
either 5-FU or FOLFOX related toxicity in the literature.Four
of these variants had good proxy SNPs in the GWAS,
although none of them showed a statistically significant
association [19]. The large confidence interval in the asso-
ciation between rs10876844 and toxicity may reflect a pos-
sible type I error. Verification by replication in large
independent data sets and fine-mapping studies, includ-
ing functional assays, is necessary to clarify the biological
mechanisms underlying these associations.
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Acute lymphoblastic leukemia (ALL)
Trevino et al. utilized a GWAS approach to identify germ-
line genetic variations associated with methotrexate
pharmacokinetics and clinical effects [21]. The discovery
cohort included 434 children with acute lymphoblastic
leukemia (ALL) enrolled and treated on St Jude Children’s
Research Hospital Total XIIIB and Total XV protocols, with
methotrexate and 6-mercaptopurine, followed by a valida-
tion cohort of 206 patients with similar characteristics.The
strongest association was on chromosome 12 with the top
two SNPs associated with the transporter gene, SLCO1B1/
OATP1B1, and ultimately methotrexate clearance. These
two SLCO1B1 SNPs remained significant (rs11045879, P =
1.7 × 10−10 and rs4149081, P = 1.7 × 10−9) after correction for
multiple testing, and were in complete LD (r2 = 1) with each
other. Eight additional SLCO1B1 SNPs were associated with
clearance (P < 0.05).These SNPs were not in LD with the top
two SNPs and were encompassed by multiple haplotype
blocks. SLCO1B1, rs11045879 T allele (OR 16.4, P = 0.004)
and the G allele at rs4149081 (OR 15.3, P = 0.03) were
each significantly associated with gastrointestinal toxicity.
Seven of the 10 interrogated SNPs remained associated in
the validation cohort. SLCO1B1 T521C was associated with
methotrexate clearance in the discovery and the com-
bined (discovery plus validation) patient cohorts (P = 1.9 ×
10−7 and P = 1.2 × 10−7, respectively). SLCO1B1 genetic vari-
ation accounted for 9.3% of the inter-patient variability in
the discovery cohort and 11.3% in the validation cohort
[21]. This locus remained a significant predictor after
adjusting for gender, race, renal function and age. Identify-
ing patients at risk of low methotrexate clearance, particu-
larly as it relates to toxicity, may be useful for monitoring
and supportive care during high dose methotrexate.
Lessons and challenges in the
post-GWAS era
Although several of the GWAS noted above have identified
potential variants associated with treatment outcome, the
biological basis of such an association is often difficult to
identify in the majority of scenarios [22]. Additionally, func-
tional studies have not always been used to aid in the
interpretation of the findings. Since SNP arrays were
designed to capture LD structure rather than functional
variants, many GWAS identify an association between the
phenotype of interest and a surrogate marker (tag SNP)
rather than the causal variant [22]. Alternatively, tag SNPs
may be used to identify LD blocks,which may be correlated
with the phenotype of interest, as noted in the study by
Kiyotani et al. [10]. Additionally, at some loci, multiple asso-
ciated risk alleles rather than a single risk allele may be
responsible for the occurrence of a particular toxicity or
influence clinical outcome. Performing functional assays
provides the mechanistic basis for the observed associa-
tions and could point towards the causal variants among
the variants within the LD block [23].
A potential solution to the identification of predictive
SNPs may involve the application of physiologically-based
modelling and neural network analyses, as seen with the
discovery of SNPs associated with human diseases [24].
The traditional approach to modelling the association
between genetic predictors and phenotype is logistic
regression. However, the number of possible interaction
terms grows exponentially as each additional variable is
included in the regression model. Alternatively, neural net-
works may offer an advantage by taking what is learned on
a given dataset about the relationship between independ-
ent variables and an outcome variable and make predic-
tions on data where the outcome variable is unknown (i.e.
optimizes the input from a larger pool of variables, weights
and connectivity of the network to generate ‘optimal
neural network architectures’ for a given data set) [25].
While, the 1000 Genomes (http://www.1000
genomes.org) and HapMap (hapmap.org) projects aim to
capture common and rare variant information in diverse
ethnic cohorts [26], they do not provide complete SNP
coverage across the entire genome, including intergenic
and non-coding regions where several of the GWAS asso-
ciations have been mapped. This may suggest that for rare
variants, or those found in intergenic regions, fine
mapping by targeted sequencing may be necessary to
capture the causal SNP that is in LD with the associated
SNP [22]. Regulatory sequences, including enhancers, pro-
moters, insulators and silencers, are becoming more
important as we begin to characterize the landscape of
susceptibility regions. For example, although many GWAS
findings tend to be located in non-coding regions and
intergenic, several of these SNPs may be in LD with
another gene which may be controlled by a regulatory
element or motif. Alternatively, they can be involved in
distant regulation of a gene, acting as trans-eQTLs (expres-
sion quantitative trait loci, see later) [22, 27]. Furthermore,
CNV regions may not be well tagged by SNP markers, and
thus may not be replicated, as noted in the study by
Fernandez-Rosadilla et al. [19].
Epigenetic influence on gene expression can also con-
tribute to gene regulation [28]. Promoter methylation,
histone tail modifications, and altered expression of non-
coding RNAs may regulate the activity of SNPs and func-
tional genetic associations. In fact, epigenetic silencing has
been shown to be the predominant mechanism of gene
silencing during tumour development for a number of
genes [29]. eQTLs, genomic loci that regulate expression
levels of mRNAs or proteins, have been shown to explain a
greater proportion of trait variance than is typically seen
for risk alleles and clinical traits. Mapping of eQTLs are
another method to test the linkage between variation in
expression and genetic polymorphism [30].
Encyclopedia of DNA Elements (ENCODE) (genome.
ucsc.edu/ENCODE), a project funded by the National
Implications of GWAS in cancer therapeutics
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Human Genome Research Institute, resulted in the identi-
fication of nearly all regions of transcription, transcription
factor association, chromatin structure and histone modi-
fication in the human genome sequence [31]. Approxi-
mately 80% of the components of the human genome, in
particular those regions outside of the well-studied
protein-coding regions, now have at least one biochemical
function associated with them and nearly 90% of associ-
ated SNPs from GWAS have been reported to be either
intergenic or intronic [23]. With the goal of delineating all
functional elements encoded in the human genome,
ENCODE provides a valuable resource in determining bio-
logical associations of GWAS hits found in non-coding
regions. In fact, 95% of the genome lies within 8 kilobases
(kb) of a DNA-protein interaction, and 99% is within 1.7 kb
of at least one of the biochemical events identified by
ENCODE [31]. Other programs, such as Haploview (http://
www.broadinstitute.org/haploview), are designed to
facilitate LD and haplotype block analysis, permutation
testing and tag SNP analysis. HaploReg (http://www.
broadinstitute.org/mammals/haploreg) and RegulomeDB
(regulome.stanford.edu) are additional tools used for
exploring annotations of the non-coding genome at
variants on haplotype blocks, including regulatory SNPs
[32]. These databases utilize information available from
ENCODE and LD information from the 1000 Genomes
Project to help researchers develop mechanistic hypoth-
eses of the impact of non-coding variants on clinical
phenotypes.
Replication in independent cohorts is critical, prefer-
ably in a separate comparable cohort of patients [33]. The
value of replication is to guard against the vulnerability of
false positives observed with common alleles with low
effect sizes [34]. Only a limited number of variants are
genuine risk alleles, and replication helps to sift these out
[35]. The initial phase of replication should test the identi-
cal index SNPs at the same direction in as similar a popu-
lation as possible, with the purpose of ruling out false
positivity. Replication in different populations can become
complicated as there are often differences in LD pattern
across populations (i.e. African Americans tend to have
smaller LD blocks), in particular if population stratification
is not taken into account. If a SNP fails to replicate in dif-
ferent populations, as is commonly seen, this may indicate
the original SNP is not a causal variant nor in LD with causal
variants in the replication population [35]. In cancer GWAS,
replication studies are particularly challenging as the study
often requires individuals with the same tumour type,
treated in the same manner, and with knowledge of con-
founders, all within a setting where the standard of care
tends to fluctuate as new therapies are tested.Additionally,
the majority of GWAS are conducted from pre-marketing
studies (i.e. phase II and III clinical trials) where the strin-
gent inclusion/exclusion criteria may hinder the replica-
tion of results and, more relevant, their translation into the
real world clinical arena. For example, the effect of
co-administered medications, age, performance status,
disease stage, comorbidities, etc. may influence the
generalizability of results and make replication of findings
very difficult. Replication of findings made in a GWAS from
a large randomized phase III clinical trial would not only be
expensive, but ethical considerations may also indicate
that a second identical trial is not feasible, as noted in
CALGB 80303 [7, 36]. However, clean and objective pheno-
type data taken from prospective phase III studies provide
a more reliable and accurate association with a genetic
variant, when found. Studies by Wu et al. [14] and Hu et al.
[17] demonstrated the feasibility in utilizing a novel three
stage design for replication. Once replicated, SNPs with a
biologically plausible association, and preferably surpass-
ing genome-wide significance, must then be validated in a
candidate gene setting, ideally from a cohort of patients
with DNA obtained prospectively [37].
Future directions
Although new biologic insights do not guarantee rapid
translation into clinical practice, each discovery is a poten-
tial first step in a translational expedition. A complete col-
lection of relevant genes and pathways in the hope of
shortening the gap between biological knowledge and
patient care is needed.
The advent of next generation sequencing techniques
is now allowing a systematic analysis of rare variants and
copy number changes across the entire genome. The goal
of targeted sequencing is to capture the causal SNP that is
in LD with the associated SNP. The probability of identify-
ing the causal SNP may be affected by the location and
boundaries of the region to be sequenced, as well as the
depth of sequence coverage across the region [22]. The
region to be sequenced can be guided by LD structure,
given that the strength of correlation between the associ-
ated SNP and causal SNP is high. Sequencing coverage of
25 times or greater may be required,particularly in the case
of sequencing-based genotyping rather than variant
discovery [22].
A reservoir of observational studies and randomized
clinical trials provides an extensive resource for pharm-
acogenomic GWAS of drug safety and efficacy [38].Particu-
larly, large prospective randomized clinical trials allow for
improved measurement of drug exposure and concise
ascertainment of phenotype. Randomization produces
unbiased treatment assignments and ensures balanced
baseline factors, eliminating unmeasured confounding
factors [39]. Obtaining DNA prospectively and performing
GWAS within clinical trials improves efficiency by identify-
ing, measuring, and controlling for potentially interacting
variables. Experts stress that effects measured in GWAS will
be accurate only when gene–environment interactions are
taken into account [40]. While retrospective studies are
possible and may allow for larger sample sizes, they
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include inconsistent treatments and noise in the data col-
lection may confound results [36].
Secondary to the difficulty in conducting replication
studies in oncology, several groups have turned to utilizing
cell lines for interpreting GWAS findings [37]. Cell-based
models have demonstrated that chemotherapy-induced
cytotoxicity is heritable and susceptible to genetic
changes [41, 42]. In particular, HapMap lymphoblastoid cell
lines (LCLs) are rich in genetic information and offer the
opportunity to study functional in silico discovery, as well
as replication [4]. Their ease of manipulation, extensive
genotype catalogues and lack of in vivo confounders
found in patient samples make LCLs attractive alternatives
for discovery and/or replication [43]. Wheeler et al. identi-
fied significant overlap between clinical and LCL studies,
thus confirming a role for the LCL model in the analysis of
at least a subset of genes involved in patient paclitaxel
response [43]. Brown et al. performed a GWAS utilizing
516 LCLs to assess cytotoxicity to temozolomide. Results
identified a genome-wide significant association (P < 10−8)
with 20 SNPs (in high LD, average r2 > 0.9) in the
O6-methylguanine-DNA methyltransferase (MGMT) gene.
Furthermore, these SNPs were found to be highly signifi-
cantly associated with both IC50 values and MGMT tran-
script levels (P < 10−25), along with a direct correlation with
temozolomide response [44]. Other studies conducted in
LCLs have identified potential SNPs correlating with
cytotoxicity, which are subsequently confirmed or denied
in a replication cohort of patients, as well as further valida-
tion in a knockdown in vitro model [45,46].Utilizing LCLs as
a method for functional in silico discovery and/or replica-
tion will prove useful, efficient, and cost-effective in
capitalizing on the benefits from GWAS. Alternatively, limi-
tations of this method exist, such as the inability to capture
environmental and non-genetic influences inherent within
the human body and tumour. While variables such as his-
tology, stage, performance status, gender, smoking status,
etc. may be adjusted in a Cox regression analysis to
account for confounding variables, the statistical power
may be low [45].
Conclusion
The success of any pharmacogenomic GWAS will be con-
tingent upon the effect size and allele frequency of genetic
variants that influence the phenotype, the sample size,
the particular population, as well as the study design.
Although the majority of cancer GWAS to date focus on
disease susceptibility, the need for better understanding
the biological evidence behind drug response, both clini-
cal outcome and risk of toxicity, is essential. Given the large
heterogeneity, debilitating toxicity and excessive treat-
ment costs, novel methods of identifying mechanisms of
variable drug response and ultimately treatment individu-
alization will be indispensable.
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